Form D · Biotechnology
Imvax, Inc.
Philadelphia, PA · CIK 0001708970
Offering snapshot reported Jul 30, 2020 · SEC filing
- Reported sold
- $112M Offering amount: $112M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 15, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 30, 2020 | Initial | $112,370,500 | No comparison | 19 | SEC filing |
| May 28, 2019 | Initial | $24,763,299 | No comparison | 16 | SEC filing |
| Jun 16, 2017 | Initial | $14,694,660 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-372102
Offer and sale of shares of preferred stock and the underlying shares of common stock issuable upon conversion thereof.
Source: Form D, filed Jul 30, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Altschuler | Director |
| David Andrews | Director, Executive |
| Ira Brind | Director |
| David Bunning | Director |
| Peter Corr | Director, Executive |
| Wendy Di Cicco | Director |
| John Furey | Director, Executive |
| Arthur W Howe | Executive |
| Ted Koutouzis | Director |
| Thomas Pfisterer | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
601 Walnut Street, Suite 440
Philadelphia, PA, 19106
Philadelphia, PA, 19106